Healthcare entity
market-trends is the sole category represented across all 3 tracked stories. Baird is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The 18-day window averages about 1.2 stories each week. They are better corroborated than the beat average, carrying 4 original sources each against 3.4 for the same window.
Last mentioned: Mar 14, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
market-trends is the sole category represented across all 3 tracked stories. Baird is the most frequent co-covered peer, appearing in 2 of the 3 tracked stories. The 18-day window averages about 1.2 stories each week. They are better corroborated than the beat average, carrying 4 original sources each against 3.4 for the same window. Their average consequence score of 5 runs below the beat's 5.8 for that window. This profile follows 3 Healthcare stories mentioning Alignment Healthcare across the period from February 25, 2026 to March 14, 2026.
Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 358 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Alignment Healthcare. Shared-story counts are live from our verified record — not editorial picks.
Insider Selling
President and another insider report share sales in regulatory filings.
Analyst Downgrade
Wall Street Zen cuts ALHC rating to Hold.
Offering Priced
Secondary offering is priced at $19.46 per share.
Secondary Offering Announced
Company announces intent to sell 13.2 million shares to raise capital.
Expected Q4 Earnings Call
Management is anticipated to provide final 2025 figures and formal guidance for the 2026 fiscal year.
Earnings Preview Release
FinancialContent and other market trackers highlight ALHC as a key stock to watch ahead of Q4 reporting.
Baird Model Update
Analysts at Baird set a bullish $59 price target for ALHC, signaling high confidence in the tech-enabled MA model.
Alignment Healthcare (NASDAQ: ALHC) has reported significant insider selling, including a 29,113-share disposal by its President, shortly after a major secondary offering. These transactions occur as the company navigates a shift in analyst sentiment and a challenging regulatory environment for Medicare Advantage providers.
Source: tickerreport.com · themarketsdaily.com
Wall Street Zen has lowered its rating on Alignment Healthcare (ALHC) to "Hold," reflecting broader caution within the Medicare Advantage sector. The downgrade comes as specialized insurers face tightening margins and regulatory shifts in the federal reimbursement landscape.
Source: themarketsdaily.com · themarketsdaily.com
Alignment Healthcare (ALHC) is set to report its fourth-quarter results, with investors focusing on membership growth and the medical loss ratio (MLR) within its tech-enabled Medicare Advantage platform. As the MA market faces regulatory headwinds, ALHC's ability to maintain clinical outcomes through its proprietary AVA software remains a critical differentiator.
Alignment Healthcare is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
